S116836 - CML - Chronic myeloid leukemia
ARTICLES
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia
December 11, 2019, PubMed
Abstract 1980: S116836 overcomes BCR-ABL T315I mutation mediated imatinib resistance in chronic myeloid leukemia
July 2018, Cancer Research
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells
July 15, 2014, PubMed
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia
December 11, 2019, PubMed
Abstract 1980: S116836 overcomes BCR-ABL T315I mutation mediated imatinib resistance in chronic myeloid leukemia
July 2018, Cancer Research
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells
July 15, 2014, PubMed
See also Mutation T315I